Lumosa Therapeutics Co., Ltd.

TPEX:6535 Stock Report

Market Cap: NT$43.7b

Lumosa Therapeutics Past Earnings Performance

Past criteria checks 0/6

Lumosa Therapeutics's earnings have been declining at an average annual rate of -9.4%, while the Pharmaceuticals industry saw earnings growing at 8.2% annually. Revenues have been declining at an average rate of 29.4% per year.

Key information

-9.4%

Earnings growth rate

-0.8%

EPS growth rate

Pharmaceuticals Industry Growth18.5%
Revenue growth rate-29.4%
Return on equity-34.3%
Net Margin-1,028.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Lumosa Therapeutics'(GTSM:6535) Share Price Is Down 47% Over The Past Five Years.

Mar 10
Lumosa Therapeutics'(GTSM:6535) Share Price Is Down 47% Over The Past Five Years.

We're Hopeful That Lumosa Therapeutics (GTSM:6535) Will Use Its Cash Wisely

Nov 24
We're Hopeful That Lumosa Therapeutics (GTSM:6535) Will Use Its Cash Wisely

Revenue & Expenses Breakdown

How Lumosa Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TPEX:6535 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2438-38955319
30 Jun 2448-28147335
31 Mar 2453-49950376
31 Dec 2357-23848369
30 Sep 2353-8644323
30 Jun 2341-12146307
31 Mar 2332-16542292
31 Dec 2227-49540280
30 Sep 2222-86238369
30 Jun 2218-23936388
31 Mar 2218-15635381
31 Dec 21179634406
30 Sep 212133933330
30 Jun 2122-17731319
31 Mar 2122-14437291
31 Dec 2022-32338317
30 Sep 20168-33346302
30 Jun 20169-36447271
31 Mar 20167-27241274
31 Dec 19172-24156238
30 Sep 1930-13459230
30 Jun 1961-6862205
31 Mar 1959-11466172
31 Dec 1861-5053131
30 Sep 1845-10946119
30 Jun 1815-14646131
31 Mar 1819-18342155
31 Dec 1735-21347173
30 Sep 1732-22545208
30 Jun 1730-24844236
31 Mar 1738-22343243
31 Dec 1612-23034244
30 Sep 1622-20430212
30 Jun 1622-23123251
31 Mar 1610-24723245
31 Dec 1510-23521241
30 Sep 150-27122264
30 Jun 150-23925222
31 Mar 150-18923176

Quality Earnings: 6535 is currently unprofitable.

Growing Profit Margin: 6535 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 6535 is unprofitable, and losses have increased over the past 5 years at a rate of 9.4% per year.

Accelerating Growth: Unable to compare 6535's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6535 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.9%).


Return on Equity

High ROE: 6535 has a negative Return on Equity (-34.27%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 14:58
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Lumosa Therapeutics Co., Ltd. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Weiyu LiCapital Securities Corporation
Hengyu FuMasterlink Securities Corp.